相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis
Marcus W. Koch et al.
MULTIPLE SCLEROSIS JOURNAL (2022)
Microglia in multiple sclerosis - pathogenesis and imaging
Laura Airas et al.
CURRENT OPINION IN NEUROLOGY (2022)
Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
Vanessa Beynon et al.
BMJ NEUROLOGY OPEN (2022)
Long-term evolution of multiple sclerosis iron rim lesions in 7 T MRI
Assunta Dal-Bianco et al.
BRAIN (2021)
Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors
Pietro Iaffaldano et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Identifying the Distinct Cognitive Phenotypes in Multiple Sclerosis
Ermelinda De Meo et al.
JAMA NEUROLOGY (2021)
Application of definitions for conversion to secondary progressive MS in a Danish nationwide population
Tine Iskov Kopp et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2021)
NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study
Timo Uphaus et al.
EBIOMEDICINE (2021)
Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data
Arman Eshaghi et al.
NATURE COMMUNICATIONS (2021)
Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort
Charidimos Tsagkas et al.
EUROPEAN JOURNAL OF NEUROLOGY (2021)
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis
Luca Prosperini et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2021)
Reliability of Outcome Measures in Clinical Trials in Secondary Progressive Multiple Sclerosis
Marcus W. Koch et al.
NEUROLOGY (2021)
Age-related adverse events of disease-modifying treatments for multiple sclerosis: A meta-regression
Luca Prosperini et al.
MULTIPLE SCLEROSIS JOURNAL (2021)
Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?
Iris Dekker et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity
Heidi Hogel et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Early clinical markers of aggressive multiple sclerosis
Charles B. Malpas et al.
BRAIN (2020)
Treatment Optimization in Multiple Sclerosis: Canadian MS Working Group Recommendations
Mark S. Freedman et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2020)
Association Between Cigarette Smoking and Multiple Sclerosis A Review
Mattia Rosso et al.
JAMA NEUROLOGY (2020)
Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis
Stefan Gingele et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
A mixed methods approach towards understanding key disease characteristics associated with the progression from RRMS to SPMS: Physicians' and patients' views
Tjalf Ziemssen et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Gadolinium enhancement on cranial MRI in multiple sclerosis is age dependent
Marcus W. Koch et al.
JOURNAL OF NEUROLOGY (2020)
Paramagnetic Rim Sign in Radiologically Isolated Syndrome
Suradech Suthiphosuwan et al.
JAMA NEUROLOGY (2020)
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosis
Ali Manouchehrinia et al.
NEUROLOGY (2020)
The 2013 clinical course descriptors for multiple sclerosis A clarification
Fred D. Lublin et al.
NEUROLOGY (2020)
The window of opportunity for treatment of progressive multiple sclerosis
Per Soelberg Sorensen et al.
CURRENT OPINION IN NEUROLOGY (2020)
Molecular signature of slowly expanding lesions in progressive multiple sclerosis
Katharina Jaeckle et al.
BRAIN (2020)
Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials
Ludwig Kappos et al.
JAMA NEUROLOGY (2020)
Improved relapse recovery in paediatric compared to adult multiple sclerosis
Tanuja Chitnis et al.
BRAIN (2020)
Aggressive multiple sclerosis (1): Towards a definition of the phenotype
Ellen Iacobaeus et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial
Bruce A. C. Cree et al.
LANCET NEUROLOGY (2020)
Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone
E. C. Foo et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2020)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial
Jerry S. Wolinsky et al.
LANCET NEUROLOGY (2020)
Predicting the profile of increasing disability in multiple sclerosis
Valentina Tomassini et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
Silent progression in disease activity-free relapsing multiple sclerosis
Bruce A. C. Cree et al.
ANNALS OF NEUROLOGY (2019)
Imaging outcome measures of neuroprotection and repair in MS
Jiwon Oh et al.
NEUROLOGY (2019)
Current therapeutic landscape in multiple sclerosis: an evolving treatment paradigm
Bruce A. C. Cree et al.
CURRENT OPINION IN NEUROLOGY (2019)
Natalizumab treatment reduces microglial activation in the white matter of the MS brain
Marcus Sucksdorff et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)
Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis
Colm Elliott et al.
BRAIN (2019)
Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis
Anand J. C. Eijlers et al.
NEUROLOGY (2019)
Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions
Colm Elliott et al.
MULTIPLE SCLEROSIS JOURNAL (2019)
MRI phenotypes in MS Longitudinal changes and miRNA signatures
Christopher C. Hemond et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2019)
Advances in brain imaging in multiple sclerosis
Rosa Cortese et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2019)
Deep gray matter volume loss drives disability worsening in multiple sclerosis
Arman Eshaghi et al.
ANNALS OF NEUROLOGY (2018)
Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study
Ludwig Kappos et al.
LANCET (2018)
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension
Raja Kapoor et al.
LANCET NEUROLOGY (2018)
Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria
Alan J. Thompson et al.
LANCET NEUROLOGY (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
New Insights into Multiple Sclerosis Clinical Course from the Topographical Model and Functional Reserve
Stephen C. Krieger et al.
NEUROLOGIC CLINICS (2018)
Spinal cord volume loss A marker of disease progression in multiple sclerosis
Charidimos Tsagkas et al.
NEUROLOGY (2018)
ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis
Xavier Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2018)
Evaluation of Microglial Activation in Multiple Sclerosis Patients Using Positron Emission Tomography
Laura Airas et al.
FRONTIERS IN NEUROLOGY (2018)
Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2018)
Vitamin D and Multiple Sclerosis: A Comprehensive Review
Martina B. Sintzel et al.
NEUROLOGY AND THERAPY (2018)
Monitoring Progressive Multiple Sclerosis with Novel Imaging Techniques
Maria Petracca et al.
NEUROLOGY AND THERAPY (2018)
Evaluation of the Effect of Fingolimod Treatment on Microglial Activation Using Serial PET Imaging in Multiple Sclerosis
Marcus Sucksdorff et al.
JOURNAL OF NUCLEAR MEDICINE (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
X. Montalban et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Meta-analysis of the Age-Dependent Efficacy of Multiple Sclerosis Treatments
Ann Marie Weideman et al.
FRONTIERS IN NEUROLOGY (2017)
Distinct brain imaging characteristics of autoantibody-mediated CNS conditions and multiple sclerosis
Maciej Jurynczyk et al.
BRAIN (2017)
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis
C. Zecca et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis
C. Zecca et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Defining secondary progressive multiple sclerosis
Johannes Lorscheider et al.
BRAIN (2016)
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Fred Lublin et al.
LANCET (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Aging and multiple sclerosis
Shaik Ahmed Sanai et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
Ayman Tourbah et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
Aging and multiple sclerosis
Shaik Ahmed Sanai et al.
MULTIPLE SCLEROSIS JOURNAL (2016)
A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta
Stefania Galassi et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2016)
Subgroups of multiple sclerosis patients with larger treatment benefits: a meta-analysis of randomized trials
A. Signori et al.
EUROPEAN JOURNAL OF NEUROLOGY (2015)
Progressive multiple sclerosis 3 Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives
Daniel Ontaneda et al.
LANCET NEUROLOGY (2015)
Progressive multiple sclerosis 1 Pathological mechanisms in progressive multiple sclerosis
Don H. Mahad et al.
LANCET NEUROLOGY (2015)
Modelling the natural history of primary progressive multiple sclerosis
Katharine E. Harding et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2015)
Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron
Lukas Haider et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2014)
MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis
Shahamat Tauhid et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
Jack Antel et al.
ACTA NEUROPATHOLOGICA (2012)
Cortical Remyelination: A New Target for Repair Therapies in Multiple Sclerosis
Ansi Chang et al.
ANNALS OF NEUROLOGY (2012)
Progressive multiple sclerosis: pathology and pathogenesis
Hans Lassmann et al.
NATURE REVIEWS NEUROLOGY (2012)
Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis
Owain W. Howell et al.
BRAIN (2011)
Intrinsic Damage to the Major White Matter Tracts in Patients with Different Clinical Phenotypes of Multiple Sclerosis: A Voxelwise Diffusion-Tensor MR Study
Paolo Preziosa et al.
RADIOLOGY (2011)
EFNS guidelines on diagnosis and management of neuromyelitis optica
J. Sellner et al.
EUROPEAN JOURNAL OF NEUROLOGY (2010)
The limits of functional reorganization in multiple sclerosis
Menno M. Schoonheim et al.
NEUROLOGY (2010)
Rituximab in Patients with Primary Progressive Multiple Sclerosis Results of a Randomized Double-Blind Placebo-Controlled Multicenter Trial
Kathleen Hawker et al.
ANNALS OF NEUROLOGY (2009)
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Josa M. Frischer et al.
BRAIN (2009)
A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis
X. Montalban et al.
MULTIPLE SCLEROSIS JOURNAL (2009)
Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology
Roberta Magliozzi et al.
BRAIN (2007)
Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial
Jerry S. Wolinsky et al.
ANNALS OF NEUROLOGY (2007)
Remyelination is extensive in a subset of multiple sclerosis patients
Peter Patrikios et al.
BRAIN (2006)
Secondary progressive multiple sclerosis: current knowledge and future challenges
M Rovaris et al.
LANCET NEUROLOGY (2006)
Cortical demyelination and diffuse white matter injury in multiple sclerosis
A Kutzelnigg et al.
BRAIN (2005)
Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial
OR Hommes et al.
LANCET (2004)
Interferon beta-1b in secondary progressive MS - A combined analysis of the two trials
L Kappos et al.
NEUROLOGY (2004)
Primary and secondary progressive multiple sclerosis
S Vukusic et al.
JOURNAL OF THE NEUROLOGICAL SCIENCES (2003)
Interferon β-1a in primary progressive MS -: An exploratory, randomized, controlled trial
SM Leary et al.
NEUROLOGY (2003)
Mitoxantrone in progressive multiple sclerosis:: a placebo-controlled, double-blind, randomised, multicentre trial
HP Hartung et al.
LANCET (2002)
Benefit of interferon β-1a on MSFC progression in secondary progressive MS
JA Cohen et al.
NEUROLOGY (2002)
Randomized controlled trial of interferon-beta-1a in secondary progressive MS - MRI results
DKB Li et al.
NEUROLOGY (2001)
Relapses and progression of disability in multiple sclerosis.
C Confavreux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
